Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
St. Jude Children's Research Hospital
Survivors with ALL and HL with identified executive function impairment will be randomized to receive stimulation with alpha tPBM + cognitive training, gamma tPBM + cognitive training or sham tPBM + cognitive training three days per week for a 2-month intervention period The tPBM will be applied to nodes in the default mode network.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed treatment for acute lymphoblastic leukemia (ALL) or Hodgkin's Lymphoma (HL) at SJCRH.
Enrolled in SJLIFE, and less than 21 years of age at diagnosis.
18 years of age or older at time of enrollment.
2 years or greater post-treatment completion of cancer directed therapy and not currently receiving any cancer directed therapy.
English language proficiency.
Access to WiFi.
Executive dysfunction defined as having an age-adjusted standard score less than 16th percentile on objectively assessed cognitive test or patient-reported executive dysfunction defined as having a standard score greater than 84th percentile within 3 years of time of enrollment.
You may not be if
Estimated intelligence score less than 80.
Currently taking medication intended to treat neurocognitive impairment (i.e., stimulants).
Major psychiatric condition.
Alcohol abuse in the past year (AUDIT) \[greater than or equal to 13 for women and greater than or equal to 15 for men\]. The Alcohol Use Disorders Identification Test (AUDIT) will be used to screen for individuals who have active alcohol-use disorders.
Drug abuse in the past year (DAST-10) \[ greater than or equal to 3 for women or men\] The Drug Abuse Screen Test (DAST-10) will be used to screen for individuals with active drug abuse.
History of neurologic condition or genetic disorder associated with neurocognitive impairment unrelated to cancer diagnosis or treatment.
Enrolled on another independent cognitive intervention protocol within the last year.
Female participants who are pregnant or lactating (determined by participant self-report due to the remote nature of this study)
Tattoo or artificial marking in the area where the device will be positioned.
Clareo Health | Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer
